In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 126456-43-7, name is (1S,2R)-1-Amino-2,3-dihydro-1H-inden-2-ol, introducing its new discovery. Safety of (1S,2R)-1-Amino-2,3-dihydro-1H-inden-2-ol
A concise and enantioselective synthesis of novel HIV-1 protease transition state mimics
Novel HIV-1 protease inhibitors have been prepared in an enantioselective manner via an Evans asymmetric aldol, Claisen rearrangement and iodolactonization. X-ray crystallographic analysis was used to confirm the absolute configuration of the newly created stereogenic centers.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 126456-43-7, and how the biochemistry of the body works.Safety of (1S,2R)-1-Amino-2,3-dihydro-1H-inden-2-ol
Reference£º
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations,
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis